Professor Richard J Ross MD FRCP

Richard Ross 2Head of Unit and Faculty Academic Lead for Innovation

Academic Unit of Diabetes, Endocrinology and Reproduction
University of Sheffield
E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
UK

Office: EU14

Tel: +44 (0)114 215 9089

Secretary Mrs Lindsey Crowson: +44 (0)114 215 9004

Email: r.j.ross@sheffield.ac.uk or l.crowson@sheffield.ac.uk

Biography

I trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew´s Hospital, London (1983-1988). I was appointed to Sheffield University in 1995 and am Head of the Unit of Diabetes and Endocrinology. I previously served on the Medical School Council as Head of Section for Endocrinology and Reproduction (2005-2008) and as Director of Sheffield Health Innovation Centre subsequently Sheffield Healthcare Gateway (2008-2018).

My research and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer therapy. I am a founding Director of two university spin-out companies; Asterion Ltd and Diurnal Plc. Served on the editorial boards of: Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-), and J Clin Endocrinol Metab (2010-2014). Council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012). Executive Committee of the European Society of Endocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), and The Growth Hormone Research Society Council (2011-2016). Currently Chief Scientific Officer and Director on the Board of Diurnal Group Plc.

Research Interests

The focus of both my clinical and basic research is on optimising endocrine hormone replacement. My group have identified and characterised uncommon mutations in the growth hormone receptor which have led to fundamental observations on the mechanism by which the growth hormone receptor signals through a pre-formed dimer. This work led to a greater understanding of the regulation of growth hormone secretion and the group have developed a long acting form of growth hormone and this work was published in Nature Medicine in 2007. The group are now actively developing a long acting growth hormone antagonist.

The Clinical Research Programme has been investigating different regimens for replacing cortisol, testosterone and oestrogen in hypopituitary, hypogonadal and adrenal insufficient patients. The group have designed modified release forms of hydrocortisone, including Infacort for the treatment of neonates and children with adrenal insufficiency and Chronocort, to replicate the normal circadian rhythm of cortisol. Infacort received a Market Authorisation from EMA in 2018 and is being marketed under the trade name Alkindi and Chronocort is currently completing phase 3 clinical trials in patients with congenital adrenal hyperplasia. Other work has examined the incidence of hypogonadism in cancer survivors and replacing testosterone in young male cancer survivors.

The Endocrine Unit consists of 6 Consultant Endocrinologists and runs a number of unique and innovative specialist clinics in the Health Care Trust including: Pituitary Clinic, Transition Clinic for Paediatric Endocrinology, Late Effects Clinic for Cancer survivors, Joint Surgical Endocrine Clinics, Obesity Clinic, Genetic Endocrine Clinic and a Pituitary Multidisciplinary Team.

Publications and Patents: 286 publications during career, Scopus h-index of 46. 35 patents granted from 7 independent patent families.

Teaching Interests

I lecture medical students in Endocrinology and supervise PhD and BMedSci students.

Professional Activities

Editorship:
Editorial Board Clinical Endocrinology 1996-2000
Editor: Growth and Growth Factors 1986-2006
Editorial Board: Journal of Endocrinological Investigation 2004-07
Editorial Board: Journal of Clinical Endocrinology & Metabolism 2010-

Advisory Boards
NICE appraisal of adult growth hormone replacement 2003-04
Member of Lilly HYPOCCS International Advisory Board 1999-2007
* Society for Endocrinology
- Society for Endocrinology Media Committee 2009=-2012
- SFE Nomination Committee 2010
- A Director of Bioscientifica (2006-2010), the company that supports the Society for Endocrinology and promotes endocrinology internationally.
- I chair the Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE 2002-2015) which is a national group undertaking major research in the management of patients with congenital adrenal hyperplasia. We completed a study of over 200 patients published in J Clin Endocrinol Metab 2010.
* University Spin Out Companies
- Founding Director Asterion Ltd, MD 2001-06, CSO 2006-
- Founding Director and now CSO of Diurnal Ltd and Director of Diurnal Plc

* National Committee Membership
- Council Member, Society for Endocrinology 1999-01
- Society for Endocrinology Clinical Subcommittee, Audit 1997-99, Program Organiser 2000-02
Treasurer of the European Society of Endocrinology (2013-2015),
The Growth Hormone Research Society Council (2011-2016).

Current Projects

  • Improving the care of patients with congenital adrenal hyperplasia and adrenal insufficiency
  • Development of long-acting biologicals including growth hormone antagonists for the treatment of acromegaly

Recent Publications

To access selected publications visit myPublications

  1. Daniel, E., Whitaker, M. J., Keevil, B., Wales, J., & Ross, R. J. (2018). Accuracy of hydrocortisone dose administration via nasogastric tube. Clinical Endocrinology. doi:10.1111/cen.13876
  2. Harrison, R. F., Debono, M., Whitaker, M. J., Keevil, B. G., Newell-Price, J., & Ross, R. J. (2018). Salivary cortisone to estimate cortisol exposure and sampling frequency required based on serum cortisol measurements. Journal of Clinical Endocrinology and Metabolism. doi:10.1210/jc.2018-01172
  3. Elder, C. J., Harrison, R. F., Cross, A. S., Vilela, R., Keevil, B. G., Wright, N. P., & Ross, R. J. (2018). Use of salivary cortisol and cortisone in the high and low dose synacthen test. Clinical Endocrinology, 88(6), 772-778. doi:10.1111/cen.13509
  4. Porter, J., Withe, M., & Ross, R. J. (2018). Immediate-release granule formulation of hydrocortisone, Alkindi®, for treatment of paediatric adrenal insufficiency (Infacort development programme). Expert Review of Endocrinology & Metabolism, 13(3), 119-124. doi:10.1080/17446651.2018.1455496
  5. Johannsson, G., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Casanueva, F. F., Chanson, P., . . . Jorgensen, J. O. L. (2018). Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 7(3), R126-R134. doi:10.1530/EC-18-0047
  6. Cross, A. S., Helen Kemp, E., White, A., Walker, L., Meredith, S., Sachdev, P., . . . Elder, C. J. (2018). International survey on high- and low-dose synacthen test and assessment of accuracy in preparing low-dose synacthen. Clinical Endocrinology. doi:10.1111/cen.13559
  7. Jenkins-Jones, S., Parviainen, L., Porter, J., Withe, M., Whitaker, M. J., Holden, S. E., . . . Ross, R. J. M. (2018). Poor compliance and increased mortality, depression and healthcare costs in patients with congenital adrenal hyperplasia. European Journal of Endocrinology, 178(4), 309-320. doi:10.1530/EJE-17-0895
  8. TN, J., MJ, W., B, K., & RJ, R. (2017). Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. Journal of Bioequivalence & Bioavailability, 10(1), 1-3. doi:10.4172/jbb.1000365
  9. Liyanarachchi, K., Ross, R., & Debono, M. (2017). Human studies on hypothalamo-pituitary-adrenal (HPA) axis. Best Practice & Research Clinical Endocrinology & Metabolism, 31(5), 459-473. doi:10.1016/j.beem.2017.10.011
  10. Neumann, U., Whitaker, M. J., Wiegand, S., Krude, H., Porter, J., Davies, M., . . . Blankenstein, O. (2017). Absorption and tolerability of taste-masked hydrocortisone granules in neonates, infants and children under 6 years of age with adrenal insufficiency. Clinical Endocrinology. doi:10.1111/cen.13447
  11. Melin, J., Parra-Guillen, Z. P., Hartung, N., Huisinga, W., Ross, R. J., Whitaker, M. J., & Kloft, C. (2017). Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. Clinical Pharmacokinetics. doi:10.1007/s40262-017-0575-8
  12. Amarawardena, W. K. M. G., Liyanarachchi, K. D., Newell-Price, J. D. C., Ross, R. J. M., Iacovazzo, D., & Debono, M. (2017). Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly. Endocrinology, Diabetes & Metabolism Case Reports. doi:10.1530/EDM-17-0067
  13. Neumann, U., Burau, D., Spielmann, S., Whitaker, M., Ross, R. J., Kloft, C., & Blankenstein, O. (2017). Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology. doi:10.1530/EJE-17-0248
  14. Karunasena, N., Margetson, D., Neal, G., Whitaker, M., & Ross, R. J. (2017). Impact of food, alcohol and pH on modified-release hydrocortisone developed to treat congenital adrenal hyperplasia.. Eur J Endocrinol. doi:10.1530/EJE-16-0948
  15. Karunasena, N., Han, T. S., Mallappa, A., Elman, M., Merke, D. P., Ross, R. J. M., & Daniel, E. (2016). Androgens correlate with increased erythropoiesis in women with congenital adrenal hyperplasia. Clinical Endocrinology, 86(1), 19-25. doi:10.1111/cen.13148
  16. Jones, C. M., Mallappa, A., Reisch, N., Nikolaou, N., Krone, N., Hughes, B. A., . . . Arlt, W. (2016). Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. The Journal of Clinical Endocrinology & Metabolism, jc.2016-2855. doi:10.1210/jc.2016-2855
  17. Wilkinson, I. R., Pradhananga, S. L., Speak, R., Artymiuk, P. J., Sayers, J. R., & Ross, R. J. (2016). A long-acting GH receptor antagonist through fusion to GH binding protein.. Sci Rep, 6. doi:10.1038/srep35072
  18. Hummel, S. R., Sadler, S., Whitaker, M. J., Ara, R. M., Dixon, S., & Ross, R. J. (2016). A model for measuring the health burden of classic congenital adrenal hyperplasia in adults. Clinical Endocrinology, 85(3), 361-398. doi:10.1111/cen.13060
  19. Porter, J., Blair, J., & Ross, R. J. (2016). Is physiological glucocorticoid replacement important in children?. Arch Dis Child. doi:10.1136/archdischild-2015-309538
  20. Christiansen, J. S., Backeljauw, P., Bidlingmaier, M., Biller, B., Boguszewski, M., Casanueva, F. F., . . . Yuen, K. C. (2016). Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. European Journal of Endocrinology, 174, C1-C8. doi:10.1530/EJE-16-0111
  21. Debono, M., Harrison, R. F., Whitaker, M. J., Eckland, D., Arlt, W., Keevil, B. G., & Ross, R. J. (2016). Salivary Cortisone Reflects Cortisol Exposure Under Physiological Conditions and After Hydrocortisone. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1469-1477. doi:10.1210/jc.2015-3694
  22. Allen, D. B., Backeljauw, P., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Burman, P., . . . Thorner, M. (2016). GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. European Journal of Endocrinology, 174(2), P1-P9. doi:10.1530/EJE-15-0873
  23. Debono, M., Mallappa, A., Gounden, V., Nella, A. A., Harrison, R. F., Crutchfield, C. A., . . . Merke, D. P. (2015). Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. European Journal of Endocrinology, 173(6), 727-737. doi:10.1530/EJE-15-0064
  24. Jenkins-Jones, S., Whitaker, M., Holden, S., Morgan, C., Ross, R., & Currie, C. (2015). The Burden of Illness of Congenital Adrenal Hyperplasia In The United Kingdom: A Retrospective, Observational Study. Value in Health, 18(7), A749. doi:10.1016/j.jval.2015.09.2896
  25. Greenfield, D. M., Blewitt, A., Coleman, R. E., Walsh, J. S., Snowden, J. A., Ross, R. J. M., & Han, T. S. (2016). Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study. Clinical Endocrinology, 84(2), 296-304. doi:10.1111/cen.12869
  26. Høybye, C., Cohen, P., Hoffman, A. R., Ross, R., Biller, B. M. K., & Christiansen, J. S. (2015). Status of long-acting-growth hormone preparations — 2015. Growth Hormone & IGF Research, 25(5), 201-206. doi:10.1016/j.ghir.2015.07.004
  27. Whitaker, M. J., Spielmann, S., Digweed, D., Huatan, H., Eckland, D., Johnson, T. N., . . . Ross, R. J. (2015). Development and Testing in Healthy Adults of Oral Hydrocortisone Granules With Taste Masking for the Treatment of Neonates and Infants With Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism, 100(4), 1681-1688. doi:10.1210/jc.2014-4060
  28. Øksnes, M., Ross, R., & Løvås, K. (2015). Optimal glucocorticoid replacement in adrenal insufficiency. Best Practice & Research Clinical Endocrinology & Metabolism, 29(1), 3-15. doi:10.1016/j.beem.2014.09.009
  29. Mallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L. -A., Digweed, D., . . . Merke, D. P. (2015). A Phase 2 Study of Chronocort, a Modified-Release Formulation of Hydrocortisone, in the Treatment of Adults With Classic Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 100(3), 1137-1145. doi:10.1210/jc.2014-3809
  30. Bielohuby, M., Zarkesh-Esfahani, S. H., Manolopoulou, J., Wirthgen, E., Walpurgis, K., Toghiany Khorasgani, M., . . . Bidlingmaier, M. (2014). Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits. Disease Models & Mechanisms, 7(11), 1263-1273. doi:10.1242/dmm.016519
  31. Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014). Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas. The Journal of Clinical Endocrinology & Metabolism, 99(12), 4462-4470. doi:10.1210/jc.2014-3007
  32. Bielohuby, M., Zarkesh-Esfahani, S. H., Manolopoulou, J., Khorasgani, M. T., Aghili, Z. S., Wilkinson, I. R., . . . Bidlingmaier, M. (2014). Rabbits Are a Suitable Animal Model for the Pre-Clinical Development of Growth Hormone Agonists and Antagonists. ENDOCRINE REVIEWS, 35(3). Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209805101181&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0bfafa3ff357b450f062b62b10c587b7
  33. Whitaker, M., Digweed, D., Spielmann, S., Huatan, H., Eckland, D., Johnson, T., . . . Ross, R. J. (2014). Infacort (R), Oral Hydrocortisone Granules with Taste Masking for the Treatment of Neonates and Infants with Adrenal Insufficiency. ENDOCRINE REVIEWS, 35(3). Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209805103273&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0bfafa3ff357b450f062b62b10c587b7
  34. Han, T. S., Conway, G. S., Willis, D. S., Krone, N. P., Rees, A., Stimson, R. H., . . . Ross, R. J. (2014). Final Height in Relation to Health Outcomes in Adults with Congenital Adrenal Hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). ENDOCRINE REVIEWS, 35(3). Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209805109278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0bfafa3ff357b450f062b62b10c587b7
  35. Mallappa, A., Daley, L. -A., Sinaii, N., Van Ryzin, C., Huatan, H., Digweed, D., . . . Merke, D. P. (2014). A Phase 2 Study of Chronocort (R), a Modified Release Formulation of Hydrocortisone, in the Treatment of Adults with Classic Congenital Adrenal Hyperplasia. ENDOCRINE REVIEWS, 35(3). Retrieved from http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209805102326&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0bfafa3ff357b450f062b62b10c587b7
  36. Han, T. S., Conway, G. S., Willis, D. S., Krone, N., Rees, D. A., Stimson, R. H., . . . Ross, R. J. (2014). Relationship Between Final Height and Health Outcomes in Adults With Congenital Adrenal Hyperplasia: United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE). The Journal of Clinical Endocrinology & Metabolism, 99(8), E1547-E1555. doi:10.1210/jc.2014-1486
  37. Greenfield, D. M., Boland, E., Ezaydi, Y., Ross, R. J. M., Ahmedzai, S. H., & Snowden, J. A. (2014). Erratum: Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplantation, 49(7), 995. doi:10.1038/bmt.2014.103
  38. Ross, R. J. M. (2014). CaHASE: a Specialist Society Led Academic Collaboration to improve the management of CAH. Clinical Endocrinology, 81(3), 334-335. doi:10.1111/cen.12485
  39. Greenfield, D. M., Boland, E., Ezaydi, Y., Ross, R. J. M., Ahmedzai, S. H., & Snowden, J. A. (2014). Endocrine, metabolic, nutritional and body composition abnormalities are common in advanced intensively-treated (transplanted) multiple myeloma. Bone Marrow Transplantation, 49(7), 907-912. doi:10.1038/bmt.2014.63
  40. Whitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014). An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.. Clinical Endocrinology, 80(4), 554-561. doi:10.1111/cen.12316
  41. Bielohuby, M., Zarkesh-Esfahani, S., Manolopoulou, J., Khorasgani, M., Aghili, Z., Wilkinson, I., . . . Bidlingmaier, M. (2014). Rabbits are a suitable animal model for the pre-clinical development of growth hormone agonists and antagonists. Experimental and Clinical Endocrinology & Diabetes, 122(03). doi:10.1055/s-0034-1372159
  42. Han, T. S., Walker, B. R., Arlt, W., & Ross, R. J. (2014). Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nature Reviews Endocrinology, 10(2), 115-124. doi:10.1038/nrendo.2013.239
  43. Cawley, P., Wilkinson, I., & Ross, R. J. (2013). Developing long-acting growth hormone formulations. Clinical Endocrinology, 79(3), 305-309. doi:10.1111/cen.12240
  44. Debono, M., Prema, A., Hughes, T. J. B., Bull, M., Ross, R. J., & Newell-Price, J. (2013). Visceral Fat Accumulation and Postdexamethasone Serum Cortisol Levels in Patients With Adrenal Incidentaloma. The Journal of Clinical Endocrinology & Metabolism, 98(6), 2383-2391. doi:10.1210/jc.2012-4276
  45. Debono, M., Chadarevian, R., Eastell, R., Ross, R. J., & Newell-Price, J. (2013). Mifepristone reduces insulin resistance in patient volunteers with adrenal incidentalomas that secrete low levels of cortisol: a pilot study.. PLoS One, 8(4), e60984. doi:10.1371/journal.pone.0060984
  46. Han, T. S., Krone, N., Willis, D. S., Conway, G. S., Hahner, S., Rees, D. A., . . . Adrenal, U. K. C. (2013). Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). EUROPEAN JOURNAL OF ENDOCRINOLOGY, 168(6), 887-893. doi:10.1530/EJE-13-0128
  47. Pradhananga, S. L., Wilkinson, I. R., Ferrandis, E., Artymiuk, P. J., Sayers, J. R., & Ross, R. J. (2013). Ligand-Receptor Fusion Dimers. Unknown Journal, 227-235. doi:10.1002/9781118354599.ch15
  48. Han, T. S., Stimson, R. H., Rees, D. A., Krone, N., Willis, D. S., Conway, G. S., . . . Ross, R. J. (2013). Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clinical Endocrinology, 78(2), 197-203. doi:10.1111/cen.12045
  49. Krone, N., Rose, I. T., Willis, D. S., Hodson, J., Wild, S. H., Doherty, E. J., . . . Han, T. S. (2013). Genotype-Phenotype Correlation in 153 Adult Patients With Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency: Analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Cohort. The Journal of Clinical Endocrinology & Metabolism, 98(2), E346-E354. doi:10.1210/jc.2012-3343
  50. Debono, M., & Ross, R. J. (2013). What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?. Clinical Endocrinology, 78(5), 659-664. doi:10.1111/cen.12117

For a full list of publications please visit myPublications